Transporter Genes and statin-induced Hepatotoxicity

Area of Science:

• Pharmacogenomics
• Drug Metabolism and Transport
• Hepatology

Background:

• Hepatotoxicity is a common reason for statin discontinuation.
• Key drug transporters, including organic anion-transporting polypeptide 1B1 (SLCO1B1), multidrug resistance protein 1 (ABCB1), and breast cancer resistance protein (ABCG2), influence statin pharmacokinetics.
• The precise role of these transporters in statin-associated hepatotoxicity requires further elucidation.

Purpose of the Study:

• To comprehensively analyze the association between hepatotoxicity and polymorphisms in SLCO1B1, ABCB1, and ABCG2 genes.
• To identify genetic markers that predict the risk of statin-induced liver injury.

Main Methods:

• Retrospective analysis of prospectively collected samples from 851 patients.
• Selection of 10 single nucleotide polymorphisms (SNPs) in SLCO1B1, 9 in ABCB1, and 12 in ABCG2.
• Development of two multivariable models: clinical factors only (Model I) and combined clinical and genetic factors (Model II), with determination of attributable risk.

Main Results:

• Hepatotoxicity occurred in 7.8% of patients (66/851).
• Model I identified lipophilic statins, atrial fibrillation, and diabetes mellitus as risk factors.
• Model II revealed significant associations with lipophilic statins, atrial fibrillation, SLCO1B1 rs11045818 A allele, SLCO1B1 rs4149035 T allele, and ABCG2 rs2622629 TT genotype.
• The SLCO1B1 rs11045818 A allele showed the highest attributable risk (93.2%).
• Model II demonstrated improved predictive accuracy (AUC 0.71) compared to Model I (AUC 0.62).

Conclusions:

• Genetic polymorphisms in drug transporter genes, particularly SLCO1B1, are significantly associated with statin-induced hepatotoxicity.
• These findings support the potential for personalized medicine in statin therapy based on genetic profiling.
• Identifying high-risk individuals through genetic screening can help mitigate adverse drug reactions.